Doravirine API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals
Doravirine API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals
1. Introduction
Doravirine is a synthetic antiretroviral pharmaceutical ingredient belonging to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. It is used in combination with other antiretroviral medicines for the treatment of HIV-1 infection.
The drug works by inhibiting HIV-1 reverse transcriptase, an enzyme required for converting viral RNA into DNA. By interfering with this process, doravirine prevents an essential stage of viral replication.
Doravirine is a pyridinone-based NNRTI developed with activity against several HIV-1 strains, including certain strains carrying resistance-associated mutations to older NNRTIs. Its use depends on the patient's treatment history and the resistance profile of the virus.
In pharmaceutical manufacturing, doravirine is used as a defined chemical active pharmaceutical ingredient in oral tablet formulations. It is available as a single-ingredient product and in combination with lamivudine and tenofovir disoproxil fumarate.
For pharmaceutical manufacturers and procurement teams, important considerations include chemical identity, assay, related substances, stereochemical and structural integrity, solid-state characteristics, residual solvents, and batch-specific documentation.
Swapnroop Drugs & Pharmaceuticals welcomes pharmaceutical-sector product enquiries and sourcing discussions. Product availability, grade, specifications, and supporting documentation should be confirmed for each specific requirement.
2. What Is Doravirine API?
Doravirine is a second-generation non-nucleoside reverse transcriptase inhibitor developed to interfere with the activity of HIV-1 reverse transcriptase.
Unlike nucleoside reverse transcriptase inhibitors, which act as nucleotide analogues, doravirine binds to a separate allosteric site on the reverse transcriptase enzyme. This changes the enzyme's functional activity and prevents efficient viral DNA synthesis.
Doravirine is commonly recognised by its development code MK-1439 and its marketed brand name Pifeltro.
Key characteristics
Product name: Doravirine
Development code: MK-1439
CAS number: 1338225-97-0
Molecular formula: C₁₇H₁₁ClF₃N₅O₃
Molecular weight: Approximately 425.75 g/mol
Pharmacological class: Non-nucleoside reverse transcriptase inhibitor
Therapeutic category: Antiretroviral
Primary target: HIV-1 reverse transcriptase
Main application: Combination treatment of HIV-1 infection
Common dosage form: Film-coated oral tablets
Doravirine is a neutral small-molecule compound. The marketed Pifeltro product contains doravirine as its active ingredient, rather than a commonly used hydrochloride or sodium salt.
3. Doravirine API – Chemical Information
| Parameter | Details |
|---|---|
| Product Name | Doravirine |
| Generic Name | Doravirine |
| Development Code | MK-1439 |
| Brand Name | Pifeltro |
| CAS Number | 1338225-97-0 |
| Molecular Formula | C₁₇H₁₁ClF₃N₅O₃ |
| Molecular Weight | 425.75 g/mol |
| IUPAC Name | 3-Chloro-5-[[1-[(4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]benzonitrile |
| Chemical Class | Pyridinone derivative |
| Pharmacological Class | NNRTI |
| Therapeutic Area | HIV treatment |
| Appearance | Product-specific specification applies |
| Water Solubility | Practically insoluble in water |
The molecular formula, molecular weight, and chemical identity are consistent with the PubChem record and the US prescribing information for Pifeltro.
4. Chemical Structure and Properties of Doravirine
Doravirine has a complex heterocyclic molecular structure containing a pyridinone ring system, a triazolone-containing side chain, a chlorinated aromatic group, and a trifluoromethyl substituent.
Its molecular structure contributes to its interaction with the allosteric binding pocket of HIV-1 reverse transcriptase.
Major structural characteristics
1. Pyridinone ring system
The pyridinone structure forms an important part of the molecular framework and contributes to the binding characteristics of doravirine.
2. Trifluoromethyl group
Doravirine contains a trifluoromethyl substituent. This fluorinated group influences the molecule's electronic and physicochemical properties.
3. Chlorinated aromatic group
The molecule contains a chlorine-substituted benzonitrile ring connected through an ether linkage.
4. Triazolone-containing side chain
The triazolone-containing portion of the molecule contributes to its heterocyclic structure and molecular recognition properties.
5. Nitrile functional group
The benzonitrile component is an important structural feature of doravirine.
Important physicochemical properties
Molecular weight: Approximately 425.75 g/mol
Molecular formula: C₁₇H₁₁ClF₃N₅O₃
Chemical type: Heterocyclic organic compound
Solubility in water: Practically insoluble
Functional groups: Pyridinone, triazolone, nitrile, ether, and fluorinated aromatic groups
The finished pharmaceutical formulation must account for the compound's limited aqueous solubility when selecting excipients and developing an appropriate oral dosage form.
5. Mechanism of Action of Doravirine
Doravirine inhibits HIV-1 reverse transcriptase through a mechanism known as non-competitive inhibition.
Reverse transcriptase is an essential viral enzyme that converts HIV RNA into DNA. This DNA can subsequently become integrated into the genetic material of the host cell.
Doravirine interferes with reverse transcriptase activity and reduces the production of viral DNA.
5.1 Binding to Reverse Transcriptase
Doravirine binds to an allosteric binding pocket on HIV-1 reverse transcriptase.
This binding site is distinct from the active site used by the enzyme to process nucleotide substrates.
5.2 Non-Competitive Enzyme Inhibition
By binding to the allosteric pocket, doravirine changes the functional activity of reverse transcriptase.
This interferes with the enzyme's ability to carry out RNA-dependent DNA polymerisation.
5.3 Inhibition of Viral DNA Synthesis
When reverse transcriptase activity is inhibited, the conversion of viral RNA into DNA is disrupted.
This reduces the production of viral DNA required for subsequent stages of HIV replication.
5.4 Selectivity for Viral Reverse Transcriptase
The FDA prescribing information reports that doravirine does not inhibit human cellular DNA polymerases alpha, beta, and mitochondrial DNA polymerase gamma in the cited biochemical evaluation.
Its activity is directed towards HIV-1 reverse transcriptase rather than these tested human polymerases.
5.5 Role in Combination Antiretroviral Therapy
Doravirine is used with other antiretroviral agents because combination therapy targets different stages of HIV replication.
Using appropriate combinations helps achieve viral suppression and reduces the likelihood of treatment failure associated with resistance.
6. Pharmaceutical Applications of Doravirine API
Doravirine has an established pharmaceutical application in HIV-1 treatment.
It is incorporated into oral antiretroviral products and combination medicines according to their respective regulatory approvals.
6.1 HIV-1 Treatment
Doravirine is used in combination with other antiretroviral agents for the treatment of HIV-1 infection.
The US-approved Pifeltro product is indicated for adults and paediatric patients weighing at least 35 kg who meet the specified treatment-history and resistance criteria.
6.2 Antiretroviral Therapy in Treatment-Naive Patients
Doravirine-containing regimens may be used in eligible patients without prior antiretroviral treatment history.
The selection of a regimen depends on clinical evaluation, resistance considerations, other medicines being used, and the relevant treatment guidelines.
6.3 Treatment Switching in Virologically Suppressed Patients
The Pifeltro label also includes use in eligible patients who are already virologically suppressed on a stable antiretroviral regimen and meet the specified conditions.
These include having no history of treatment failure and no known substitutions associated with doravirine resistance.
6.4 Fixed-Dose Combination Products
Doravirine is available in a fixed-dose combination with lamivudine and tenofovir disoproxil fumarate.
This combination provides three antiretroviral agents with complementary mechanisms of action.
6.5 Pharmaceutical Research and Development
Doravirine is relevant to pharmaceutical research involving:
HIV reverse transcriptase inhibition
NNRTI drug development
Antiviral formulation development
Drug-excipient compatibility
Analytical method development
Related-substance evaluation
Solid-state characterisation
7. Common Pharmaceutical Formulations Containing Doravirine
Doravirine is formulated primarily as an oral solid dosage form.
| Dosage Form | Example | General Application |
|---|---|---|
| Film-Coated Tablets | Pifeltro | Oral antiretroviral treatment |
| Fixed-Dose Combination Tablets | Delstrigo | Combination HIV treatment |
7.1 Pifeltro
Pifeltro is a single-ingredient film-coated tablet containing 100 mg of doravirine.
The US prescribing information describes the product as an oral tablet used in combination with other antiretroviral medicines.
7.2 Delstrigo
Delstrigo is a fixed-dose combination product containing:
Doravirine: 100 mg
Lamivudine: 300 mg
Tenofovir disoproxil fumarate: 300 mg
The three ingredients act through different mechanisms involved in the HIV replication cycle.
These strengths describe the specific marketed formulation and should not be treated as universal requirements for every product or market.
8. Doravirine in Fixed-Dose Combination Products
Fixed-dose combinations are important in antiretroviral treatment because they bring multiple active ingredients into one pharmaceutical dosage form.
Doravirine is combined with lamivudine and tenofovir disoproxil fumarate in Delstrigo.
8.1 Doravirine
Doravirine inhibits HIV-1 reverse transcriptase through non-competitive allosteric inhibition.
8.2 Lamivudine
Lamivudine is a nucleoside reverse transcriptase inhibitor. It interferes with viral DNA synthesis through a mechanism different from doravirine.
8.3 Tenofovir Disoproxil Fumarate
Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor prodrug. Following conversion to its active form, it interferes with HIV reverse transcriptase activity.
8.4 Formulation Development Considerations
Manufacturers developing fixed-dose combination products should evaluate:
API identity and purity
Compatibility between active ingredients
Excipient compatibility
Blend uniformity
Content uniformity
Dissolution characteristics
Chemical and physical stability
Moisture sensitivity
Packaging compatibility
Regulatory requirements
Each combination product requires an independent formulation and quality-control strategy.
9. Manufacturing and Processing Considerations
Doravirine is a synthetic small-molecule pharmaceutical ingredient. Its manufacturing involves controlled chemical synthesis, purification, isolation, and final quality evaluation.
The precise manufacturing route and process conditions depend on the validated manufacturing process.
9.1 Starting Material Qualification
Starting materials should be evaluated before entering the manufacturing process.
Important considerations include:
Chemical identity
Purity
Related impurities
Supplier qualification
Batch traceability
Compliance with the approved specification
9.2 Chemical Synthesis
The synthesis involves controlled chemical transformations to construct the doravirine molecular framework.
The process must be designed to maintain the required chemical identity and control unwanted reaction-related impurities.
9.3 Intermediate Control
Intermediate materials should be evaluated at appropriate manufacturing stages.
Relevant controls may include identity, assay, impurity profile, and other process-specific quality parameters.
9.4 Purification
Purification operations remove residual starting materials, intermediates, and process-related impurities.
Suitable purification controls are important for achieving the required final API quality.
9.5 Crystallisation and Isolation
Crystallisation and isolation operations produce the final solid material.
Process conditions can influence particle characteristics, crystalline properties, and batch consistency.
9.6 Drying and Packaging
Drying and packaging should be performed under controlled conditions to maintain material quality and prevent contamination.
The packaging system should protect the API during storage and transportation.
Note: This is a general pharmaceutical manufacturing overview, not a validated manufacturing procedure or a claim regarding SDP's manufacturing capabilities.
10. Quality Control and Testing of Doravirine API
Quality control is essential for ensuring that doravirine meets its applicable pharmaceutical specification.
Testing should evaluate chemical identity, assay, impurity profile, physical properties, and other relevant quality attributes.
10.1 Identification Testing
Identification testing confirms that the material corresponds to doravirine.
Possible analytical approaches include:
Infrared spectroscopy
HPLC identification
Mass spectrometry
Other applicable validated procedures
10.2 Assay Testing
Assay testing determines the quantity of doravirine present in the material.
The analytical method and acceptance criteria should follow the applicable current pharmacopoeial monograph, approved specification, or customer-approved quality standard.
10.3 Related Substances
Related-substance testing evaluates impurities introduced during synthesis, purification, or storage.
Chromatographic techniques are commonly used to separate and quantify relevant impurities.
10.4 Residual Solvents
Residual solvent testing evaluates solvents that may remain following chemical synthesis and purification.
The requirements should follow the applicable specification and relevant ICH Q3C guidance.
10.5 Water Content
Water-content testing helps evaluate the material's quality and suitability for pharmaceutical processing.
A suitable analytical method should be selected according to the approved specification.
10.6 Solid-State Characterisation
Solid-state characterisation may be relevant to the evaluation of crystalline form, particle properties, and physical consistency.
Possible techniques include:
Powder X-ray diffraction
Differential scanning calorimetry
Thermogravimetric analysis
Particle-size analysis, where required
10.7 Packaging Integrity
Packaging should be evaluated for correct closure, labelling, batch traceability, and protection against contamination.
11. Analytical Methods Used for Doravirine API
Several analytical methods may be used to evaluate doravirine.
| Analytical Method | Purpose |
|---|---|
| HPLC | Assay and related-substances analysis |
| FTIR Spectroscopy | Chemical identification |
| LC-MS | Molecular identity and impurity characterisation |
| UV-Visible Spectroscopy | Selected quantitative analytical applications |
| Karl Fischer Titration | Water-content determination |
| Gas Chromatography | Residual solvent analysis |
| Powder X-ray Diffraction | Crystalline-form evaluation |
| DSC | Thermal characterisation |
| TGA | Thermal and volatile-content assessment |
The final analytical programme should be based on the current applicable specification, validated methods, and intended pharmaceutical application.
12. Storage and Handling of Doravirine API
Proper storage and handling are important for maintaining the quality and integrity of doravirine.
The API's approved storage conditions should be established using its own specification and supporting stability data.
Storage considerations
Store in suitable, well-closed containers.
Protect the material from contamination.
Follow the approved storage conditions.
Maintain appropriate warehouse controls.
Avoid unnecessary exposure to unsuitable environmental conditions.
Follow supplier packaging recommendations.
Maintain batch identification and traceability.
Handling precautions
Personnel handling doravirine should:
Consult the current Safety Data Sheet.
Use suitable protective gloves.
Wear appropriate eye protection.
Avoid unnecessary dust generation.
Prevent accidental ingestion and direct exposure.
Follow workplace hygiene procedures.
Use approved sampling and dispensing controls.
The storage conditions for the bulk API should not automatically be assumed to be identical to those of the finished Pifeltro or Delstrigo products.
13. Safety and Regulatory Considerations
Doravirine is a prescription antiretroviral medicine. Its development and use are governed by product-specific prescribing information and applicable national regulations.
13.1 Severe Skin Reactions
The current US prescribing information reports severe skin reactions, including:
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Drug rash with eosinophilia and systemic symptoms (DRESS)
These reactions require appropriate clinical assessment and management.
13.2 Drug Interactions
Doravirine exposure can be significantly reduced by strong CYP3A enzyme inducers.
The US prescribing information identifies examples including:
Rifampin
Rifapentine
Carbamazepine
Oxcarbazepine
Phenobarbital
Phenytoin
Enzalutamide
Mitotane
St. John's wort
Such interactions can reduce doravirine concentrations and potentially compromise antiviral effectiveness.
13.3 Immune Reconstitution Inflammatory Syndrome
Immune reconstitution syndrome has been reported during combination antiretroviral treatment.
It may occur when the immune system begins to recover and responds to previously existing or residual infections.
13.4 Resistance Considerations
As with other antiretroviral medicines, HIV can develop resistance-associated mutations.
Treatment selection should consider relevant resistance information and the patient's antiretroviral history.
13.5 Regulatory Considerations for Manufacturers
Pharmaceutical manufacturers should evaluate:
Applicable GMP requirements
API identity and purity
Related-substance controls
Residual solvent requirements
Stability data
Validated analytical methods
Packaging qualification
Batch traceability
Regulatory filing requirements
Change-control procedures
The applicable regulatory requirements vary according to the intended market and product type.
14. Doravirine Compared with Other NNRTIs
Doravirine belongs to the non-nucleoside reverse transcriptase inhibitor class. Other medicines in this class include efavirenz, nevirapine, rilpivirine, and etravirine.
These medicines share a general therapeutic target but differ in chemical structure, pharmacological properties, resistance profiles, and clinical use.
| Drug | Therapeutic Class | General Description |
|---|---|---|
| Doravirine | NNRTI | Pyridinone-based HIV-1 reverse transcriptase inhibitor |
| Efavirenz | NNRTI | Earlier-generation antiretroviral medicine |
| Nevirapine | NNRTI | HIV reverse transcriptase inhibitor |
| Rilpivirine | NNRTI | Diarylpyrimidine-based antiretroviral |
| Etravirine | NNRTI | Antiretroviral with activity against selected NNRTI-resistant HIV strains |
These active ingredients are not automatically interchangeable. Their selection and use must follow the relevant treatment guidelines, product approvals, and resistance considerations.
15. Pharmaceutical Procurement Considerations
Pharmaceutical manufacturers and procurement teams sourcing doravirine should evaluate product identity, quality, documentation, and regulatory suitability.
15.1 Confirm Chemical Identity
Verify that the required material is doravirine, CAS 1338225-97-0.
15.2 Confirm the Required Grade
Identify the intended pharmaceutical grade and applicable customer or pharmacopoeial specification.
15.3 Review the Certificate of Analysis
A batch-specific Certificate of Analysis should include actual test results, analytical methods, and acceptance criteria.
15.4 Evaluate Related Substances
Review the impurity profile and confirm that relevant impurities are controlled using suitable analytical methods.
15.5 Review Residual Solvents
Evaluate residual solvent results according to the manufacturing process and applicable regulatory requirements.
15.6 Assess Physical Characteristics
Where required, review solid-state characteristics, particle properties, and other physical parameters relevant to formulation development.
15.7 Verify Supplier Documentation
Depending on the intended application, buyers may request:
Batch-specific Certificate of Analysis
Product specification
Safety Data Sheet
Manufacturing and testing information
Stability data
Relevant compliance declarations
Packaging details
15.8 Confirm Destination-Market Requirements
Verify the relevant regulatory requirements, documentation, labelling, and transportation conditions before procurement.
16. Doravirine API Market and Pharmaceutical Industry Relevance
Doravirine is an important antiretroviral ingredient because of its role in NNRTI-based HIV treatment regimens.
Its availability as a single-ingredient product and as part of a fixed-dose combination makes it relevant to pharmaceutical manufacturers involved in HIV treatment products.
Important industry considerations include:
Consistent chemical quality
Reliable API identification
Controlled related substances
Residual solvent management
Validated analytical testing
Solid-state characterisation
Formulation compatibility
Stability assessment
Regulatory compliance
Complete batch documentation
For pharmaceutical procurement teams, selecting an appropriate API requires attention to both chemical quality and the regulatory requirements of the destination market.
17. Doravirine API Enquiries – Swapnroop Drugs & Pharmaceuticals
Swapnroop Drugs & Pharmaceuticals welcomes product-related business enquiries from pharmaceutical manufacturers, formulation developers, distributors, and procurement professionals.
For a Doravirine API enquiry, buyers should specify:
Product name: Doravirine
CAS number: 1338225-97-0
Molecular formula: C₁₇H₁₁ClF₃N₅O₃
Molecular weight: 425.75 g/mol
Required pharmaceutical grade
Applicable quality specification
Required quantity
Intended formulation
Documentation requirements
Destination market
Product identity, grade, availability, supporting documentation, and commercial terms should be confirmed directly before any purchase commitment.
Contact Swapnroop Drugs & Pharmaceuticals for product-related business enquiries and sourcing discussions.
18. Frequently Asked Questions (FAQs)
Q1. What is Doravirine API?
Doravirine is a synthetic antiretroviral pharmaceutical ingredient belonging to the non-nucleoside reverse transcriptase inhibitor class. It is used in combination with other medicines for the treatment of HIV-1 infection.
Q2. What is the CAS number of Doravirine?
The CAS number of doravirine is 1338225-97-0.
Q3. What is the molecular formula of Doravirine?
The molecular formula is C₁₇H₁₁ClF₃N₅O₃.
Q4. What is the molecular weight of Doravirine?
The molecular weight of doravirine is approximately 425.75 g/mol.
Q5. What is the brand name of Doravirine?
Pifeltro is a marketed single-ingredient product containing doravirine. Delstrigo is a fixed-dose combination containing doravirine, lamivudine, and tenofovir disoproxil fumarate.
Q6. How does Doravirine work?
Doravirine inhibits HIV-1 reverse transcriptase through non-competitive inhibition. It binds to an allosteric site on the enzyme and interferes with viral DNA synthesis.
Q7. What is the pharmaceutical application of Doravirine?
Doravirine is used in combination with other antiretroviral medicines for the treatment of HIV-1 infection in eligible patients.
Q8. Is Doravirine an NNRTI?
Yes. Doravirine belongs to the non-nucleoside reverse transcriptase inhibitor class.
Q9. Is Doravirine available in combination products?
Yes. Doravirine is included in Delstrigo, a fixed-dose combination with lamivudine and tenofovir disoproxil fumarate.
Q10. What quality tests are important for Doravirine API?
Important tests include identification, assay, related substances, residual solvents, water content, and physical or solid-state characterisation where required.
Q11. What are important regulatory considerations for Doravirine?
Manufacturers should evaluate GMP requirements, API quality, analytical validation, impurity controls, stability, regulatory documentation, and destination-market requirements.
Q12. What documents should buyers review when sourcing Doravirine API?
Buyers should review a batch-specific Certificate of Analysis, product specification, Safety Data Sheet, manufacturing and testing information, stability data, and relevant compliance documentation.
Conclusion
Doravirine is a pyridinone-based non-nucleoside reverse transcriptase inhibitor used in combination antiretroviral therapy for HIV-1 infection. Its mechanism involves non-competitive inhibition of HIV-1 reverse transcriptase, which interrupts viral DNA synthesis.
With a molecular formula of C₁₇H₁₁ClF₃N₅O₃, a molecular weight of approximately 425.75 g/mol, and CAS number 1338225-97-0, doravirine is a specialised small-molecule API used in oral antiretroviral products.
For pharmaceutical manufacturers, important quality considerations include chemical identity, assay, related substances, residual solvents, solid-state characteristics, stability, and batch documentation.
Swapnroop Drugs & Pharmaceuticals welcomes product-related business enquiries from pharmaceutical manufacturers, distributors, and procurement professionals. Product grade, availability, documentation, and commercial details should be verified before procurement.

Comments
Post a Comment